CO7141435A2 - Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona - Google Patents
Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-onaInfo
- Publication number
- CO7141435A2 CO7141435A2 CO14262433A CO14262433A CO7141435A2 CO 7141435 A2 CO7141435 A2 CO 7141435A2 CO 14262433 A CO14262433 A CO 14262433A CO 14262433 A CO14262433 A CO 14262433A CO 7141435 A2 CO7141435 A2 CO 7141435A2
- Authority
- CO
- Colombia
- Prior art keywords
- lower alkyl
- halogen
- substituted
- oacute
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula general (I), en la que R1 es hidrógeno, halógeno, alquilo inferior, alcoxi inferior, alcoxi inferior sustituido por halógeno o ciano; R2 es hidrógeno, alquilo inferior o alquilo inferior sustituido por halógeno; R3 es fenilo, benzo[1,3]dioxolilo, 2,3-dihidro-benzofuran-5-ilo o un heteroarilo de 5 ó 6 eslabones, dichos grupos fenilo y heteroarilo de 5 ó 6 eslabones pueden estar sustituidos por uno o más sustituyentes elegidos entre ciano, nitro, amino y di(alquilo inferior)-amino, (alquilo inferior)-sulfonilo, alcoxi inferior, alcoxi inferior sustituido por halógeno, halógeno, alquilo inferior, alquilo inferior sustituido por halógeno o alquilo inferior sustituido por hidroxilo; X es -CH(alquilo inferior)-, -CH2-, -CH2CH2- o CH(alquilo inferior)CH2-; R es hidrógeno o alquilo inferior; n es el número 1 ó 2; o una sal de adición de ácido farmacéuticamente aceptable, una mezcla racémica o su enantiómero correspondiente y/o sus isómeros ópticos. Los compuestos pueden utilizarse para el tratamiento de la esquizofrenia, los trastornos de personalidad obsesivo-compulsivos, la depresión mayor, los trastornos bipolares, los trastornos de ansiedad, el envejecimiento normal, la epilepsia, la degeneración de la retina, la lesión cerebral traumática, la lesión de la espina dorsal, el trastorno de estrés post-traumático, el trastorno de pánico, la enfermedad de Parkinson, la demencia, la enfermedad de Alzheimer, el desequilibrio cognitivo leve, la disfunción cognitiva inducida por la quimioterapia, el síndrome de Down, los trastornos del espectro autista, la pérdida auditiva, el tintineo, la ataxia espinocerebelar, la esclerosis lateral amiotrófica, la esclerosis múltiple, la enfermedad de Huntington, la apoplejía, la terapia radiactiva, el estrés crónico, el abuso de drogas neuroactivas, por ejemplo el alcohol, los opiáceos, la metanfetamina, fenciclidina y cocaína.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179381 | 2012-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7141435A2 true CO7141435A2 (es) | 2014-12-12 |
Family
ID=48918402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14262433A CO7141435A2 (es) | 2012-08-06 | 2014-11-28 | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9284321B2 (es) |
| EP (1) | EP2880036B1 (es) |
| JP (1) | JP5974177B2 (es) |
| KR (1) | KR101716062B1 (es) |
| CN (1) | CN104540829B (es) |
| AR (1) | AR092041A1 (es) |
| AU (1) | AU2013301577B2 (es) |
| BR (1) | BR112015000313A2 (es) |
| CA (1) | CA2880682A1 (es) |
| CL (1) | CL2015000143A1 (es) |
| CO (1) | CO7141435A2 (es) |
| CR (1) | CR20140545A (es) |
| EA (1) | EA025884B1 (es) |
| HK (1) | HK1206355A1 (es) |
| IL (1) | IL236808B (es) |
| MA (1) | MA37791B1 (es) |
| MX (1) | MX362184B (es) |
| MY (1) | MY185216A (es) |
| NZ (1) | NZ703192A (es) |
| PE (1) | PE20150341A1 (es) |
| PH (1) | PH12015500059B1 (es) |
| SG (1) | SG11201408529VA (es) |
| TW (1) | TWI506027B (es) |
| UA (1) | UA113013C2 (es) |
| WO (1) | WO2014023674A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506420WA (en) * | 2013-02-18 | 2015-09-29 | Theranos Inc | Image analysis and measurement of biological samples |
| KR101767329B1 (ko) * | 2013-04-02 | 2017-08-10 | 에프. 호프만-라 로슈 아게 | 피페라지노[1,2-a]인돌-1-온 및 [1,4]다이아제피노[1,2-a]인돌-1-온 |
| CA2917628A1 (en) * | 2013-09-12 | 2015-03-19 | F. Hoffmann-La Roche Ag | Indol-carboxamide derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1965981C3 (de) * | 1968-02-13 | 1978-08-31 | Sumitomo Chemical Co., Ltd., Osaka (Japan) | 9-Phenyl-lO-oxopiperazino [l,2-a]-indole und Verfahren zu ihrer Herstellung |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| AU2006324089A1 (en) * | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| MX2009004898A (es) * | 2006-11-09 | 2009-05-19 | Hoffmann La Roche | Derivados de indol y de benzofurano-2-carboxamida. |
| BR112013000414A2 (pt) | 2010-07-07 | 2016-05-17 | Univ Texas | compostos proneurogênicos |
| KR101767329B1 (ko) * | 2013-04-02 | 2017-08-10 | 에프. 호프만-라 로슈 아게 | 피페라지노[1,2-a]인돌-1-온 및 [1,4]다이아제피노[1,2-a]인돌-1-온 |
-
2013
- 2013-08-05 TW TW102128001A patent/TWI506027B/zh not_active IP Right Cessation
- 2013-08-05 BR BR112015000313A patent/BR112015000313A2/pt not_active Application Discontinuation
- 2013-08-05 PE PE2015000024A patent/PE20150341A1/es active IP Right Grant
- 2013-08-05 MX MX2015001318A patent/MX362184B/es active IP Right Grant
- 2013-08-05 SG SG11201408529VA patent/SG11201408529VA/en unknown
- 2013-08-05 KR KR1020157003112A patent/KR101716062B1/ko active IP Right Grant
- 2013-08-05 CN CN201380041546.5A patent/CN104540829B/zh active Active
- 2013-08-05 CA CA2880682A patent/CA2880682A1/en not_active Abandoned
- 2013-08-05 EP EP13745648.9A patent/EP2880036B1/en active Active
- 2013-08-05 NZ NZ703192A patent/NZ703192A/en not_active IP Right Cessation
- 2013-08-05 EA EA201590125A patent/EA025884B1/ru not_active IP Right Cessation
- 2013-08-05 AU AU2013301577A patent/AU2013301577B2/en not_active Ceased
- 2013-08-05 AR ARP130102771A patent/AR092041A1/es unknown
- 2013-08-05 MY MYPI2014003519A patent/MY185216A/en unknown
- 2013-08-05 UA UAA201501071A patent/UA113013C2/uk unknown
- 2013-08-05 WO PCT/EP2013/066344 patent/WO2014023674A1/en active Application Filing
- 2013-08-05 JP JP2015525846A patent/JP5974177B2/ja active Active
-
2014
- 2014-11-27 CR CR20140545A patent/CR20140545A/es unknown
- 2014-11-28 CO CO14262433A patent/CO7141435A2/es unknown
-
2015
- 2015-01-09 PH PH12015500059A patent/PH12015500059B1/en unknown
- 2015-01-19 IL IL236808A patent/IL236808B/en not_active IP Right Cessation
- 2015-01-20 MA MA37791A patent/MA37791B1/fr unknown
- 2015-01-21 CL CL2015000143A patent/CL2015000143A1/es unknown
- 2015-02-04 US US14/614,232 patent/US9284321B2/en active Active
- 2015-07-24 HK HK15107077.4A patent/HK1206355A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015004942A2 (pt) | benzimidazóis como agentes ativos do snc | |
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| MX362532B (es) | Derivados de 1,7-naftiridina. | |
| MX2015015052A (es) | Derivados de isoquinolina que estimulan la neurogenesis. | |
| MX2015006364A (es) | 1,6-naftiridinas sustituidas. | |
| AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
| MY186124A (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
| BR112015010412A2 (pt) | compostos heteroaromáticos e seu uso como ligantes de dopamina d1 | |
| MX2016008983A (es) | Peliculas termocontraibles de barrera de multicapa pvdc. | |
| HRP20151273T1 (hr) | Heterocikliäśki spojevi fenoksilmetila | |
| CO7141435A2 (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona | |
| AR093576A1 (es) | Derivados heterociclicos sustituidos | |
| BR112017022568A2 (pt) | compostos e seus usos como inibidores de bace1 | |
| AR064739A1 (es) | Compuesto de [1,2,3] -benzotriazinona-3- sustituido para mejorar las respuestas sinapticas glutamatergicas | |
| AR106588A1 (es) | Derivados de indolin-2-ona para el tratamiento de enfermedades del snc | |
| AR106590A1 (es) | Derivados de indolin-2-ona | |
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| BR112015008200A2 (pt) | derivados de imidazopiridina | |
| MX2015013915A (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. | |
| MX2016001528A (es) | Derivados de indol-carboxamida. | |
| MX363461B (es) | Derivados de benzisoxazol como moduladores de la neurogénesis y el uso de los mismos en el tratamiento de enfermedades neurológicas y trastornos neuropsiquiátricos. | |
| TH165816A (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท | |
| TH165816B (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท |